Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study of AK117/Placebo in Combination With Azacitidine in Patients With Newly Diagnosed Higher-risk Myelodysplastic Syndromes

NCT06196203 is registered in ClinicalTrials.gov with Akeso as lead sponsor.

NCT NCT06196203
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06196203 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study of AK117/Placebo in Combination With Azacitidine in Patients With Newly Diagnosed Higher-risk Myelodysplastic Syndromes
Lead sponsor
Akeso
Phase
Phase 2
Overall status
Recruiting
Start date
February 7, 2024
Completion date
June 30, 2026
Enrollment
90 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

higher-risk myelodysplastic syndromes